Chronic Pain Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Players - Paradigm Biopharmaceuticals, Noven Pharmaceuticals, Pfizer, Biogen, Tonix Pharmaceuticals, Amzell, Bayer, and Others
According to DelveInsight’s analysis, the growth of the chronic pain market is expected to be mainly driven by increasing prevalence of diabetes and cancer, rise in awareness and access to treatment, alternative options (such as a novel therapeutic agent) to addictive opioids, holistic approach, efforts by the organization and upsurge in the geriatric population.
New York, USA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- *Chronic Pain Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Players - Paradigm Biopharmaceuticals, Noven Pharmaceuticals, Pfizer, Biogen, Tonix Pharmaceuticals, Amzell, Bayer, and Others*
*According to DelveInsight’s analysis, the growth of the chronic pain market is expected to be mainly driven by increasing prevalence of diabetes and cancer, rise in awareness and access to treatment, alternative options (such as a novel therapeutic agent) to addictive opioids, holistic approach, efforts by the organization and upsurge in the geriatric population.*
DelveInsight’s *Chronic Pain Market Insights* report includes a comprehensive understanding of current treatment practices, chronic pain emerging drugs, market share of individual therapies, and current and forecasted chronic pain market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
*Key Takeaways from the Chronic Pain Market Report*
· According to DelveInsight's analysis, the market size for chronic pain across the 7MM is expected to grow with a significant CAGR by 2032.
· DelveInsight's analysis reveals that the overall diagnosed population of chronic pain in the US was reported as *36 million* in 2022.
· Prominent companies working in the domain of chronic pain, including *Paradigm Biopharmaceuticals, Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Propella Therapeutics, Amzell, Sorrento Therapeutics, Bayer, Lexicon Pharmaceuticals, Tetra Bio-Pharma, Pure Green Pharmaceuticals, Eli Lilly and Company, Neurofix Pharma, Stayble Therapeutics, Biosplice Therapeutics, Wex Pharmaceuticals, EMD Serono Research & Development Institute, Nordic Bioscience A/S, Xalud Therapeutics, Tris Pharma*, and others, are actively working on innovative drugs for chronic pain. These novel chronic pain therapies are anticipated to enter the chronic pain market in the forecast period and are expected to change the market.
· Some of the key therapies for chronic pain treatment include *ZILOSUL (pentosan polysulfate sodium), HP-5000 (Diclofenac sodium), Reboxetine (AXS-14), CINGAL, Vixotrigine (BIIB074), TNX-102 SL, TLC599, CNTX-4975, BRIXADI (Buprenorphine, CAM2038), CGS-200-5, AMZ001, Resiniferatoxin (RTX), BAY2395840, LX-9211, QIXLEEF (PPP001), CBD, LY3556050 (CNTX-0290), NFX88, STA363, Lorecivivint (SM04690), Halneuron, Sprifermin, XT-150, Cebranopadol (PRK-101)**, *and others.
Discover which therapies are expected to grab the chronic pain market share @ *Chronic Pain Market Report*
*Chronic Pain Overview*
The International Association for the Study of Pain (IASP) defines pain as an unpleasant sensory and emotional encounter linked to actual or potential tissue damage, or expressed in terms of such damage. It can arise from injury or from the brain's inability to properly process pain signals. Chronic pain often manifests gradually and gives rise to symptoms such as fatigue, sleep disturbances, decreased appetite, loss of taste for food, weight loss, reduced libido, and constipation. Prolonged, persistent pain may contribute to the development of depression and anxiety, disrupting various aspects of daily life. Individuals experiencing chronic pain may become inactive, withdraw socially, and become overly focused on their physical health. The resulting psychological and social impairment can be severe, leading to a virtual loss of functionality. Typically, a diagnosis of chronic pain is not made until the patient has consistently experienced pain for three to six months. The diagnostic process often involves a series of tests, procedures, and a comprehensive review of symptoms and medical history. The specific tests conducted by the doctor depend on the location and cause of the pain, as well as other accompanying symptoms. These tests may encompass blood tests, imaging, and nerve testing.
*Chronic Pain Epidemiology Segmentation*
The chronic pain epidemiology section provides insights into the historical and current chronic pain patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The *chronic pain market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
· Total Prevalent Cases of Chronic Pain
· Total Diagnosed Cases of Chronic Pain
· Severity-specific Cases of Chronic Pain
· Age-specific Cases of Chronic Pain
· Cause-specific Cases of Chronic Pain
Download the report to understand which factors are driving chronic pain epidemiology trends @ *Chronic Pain Epidemiological Insights*
*Chronic Pain Treatment Market *
There are various approaches to managing chronic, severe, and persistent pain, encompassing pharmacological, adjunct, non-pharmacological, and interventional treatments. The range of pharmacological options for addressing chronic pain is extensive and includes non-opioid analgesics like *non-steroidal anti-inflammatories (NSAIDs), acetaminophen, and aspirin*. Additionally, medications such as *tramadol, opioids, and antiepileptic drugs (such as gabapentin or pregabalin)* may prove beneficial. Moreover, antidepressants like tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors (SNRIs), topical analgesics, muscle relaxers, N-methyl-d-aspartate (NMDA) receptor antagonists, and alpha 2 adrenergic agonists are also potential pharmacological therapies for addressing chronic pain.
Effectively managing pain, especially in cases of chronic pain, is most successfully achieved through an approach that prioritizes the patient and integrates various disciplines, which may involve the use of pharmacotherapy. Generally, medications for pain management can be broadly categorized into nonopioids and opioids. Approved drugs for addressing chronic pain stemming from various causes include *EMGALITY (galcanezumab-gnlm), AIMOVIG (Eptinezumab), TARLIGE (Mirogabalin besylate), LYRICA (pregabalin), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), PENNSAID, AIMOVIG (Erenumab-aooe), AJOVY (Fremanezumab), VYEPTI (Eptinezumab), and the recently approved QULIPTA (atogepant)*.
To address unfulfilled market demands and enhance treatment options for Chronic Pain, numerous market participants are actively engaged in developing innovative single-agent molecules or exploring combinations and dosage adjustments for established therapies. The study anticipates the introduction of multiple therapies, which is likely to propel market expansion throughout the research duration.
Learn more about the FDA-approved drugs for chronic pain @ *Drugs for* *Chronic Pain Treatment** *
*Key Chronic Pain Therapies and Companies*
· ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals
· HP-5000 (Diclofenac sodium): Noven Pharmaceuticals
· Reboxetine (AXS-14): Pfizer
· CINGAL: Anika Therapeutics
· Vixotrigine (BIIB074): Biogen
· TNX-102 SL: Tonix Pharmaceuticals
· TLC599: Taiwan Liposome Company
· CNTX-4975: Centrexion Therapeutics
· BRIXADI (Buprenorphine, CAM2038): Braeburn Pharmaceuticals
· CGS-200-5: Propella Therapeutics
· AMZ001: Amzell
· Resiniferatoxin (RTX): Sorrento Therapeutics
· BAY2395840: Bayer
· LX-9211: Lexicon Pharmaceuticals
· QIXLEEF (PPP001): Tetra Bio-Pharma
· CBD: Pure Green Pharmaceuticals
· LY3556050 (CNTX-0290): Eli Lilly and Company
· NFX88: Neurofix Pharma
· STA363: Stayble Therapeutics
· Lorecivivint (SM04690): Biosplice Therapeutics
· Halneuron: Wex Pharmaceuticals
· Sprifermin: EMD Serono Research & Development Institute/Nordic Bioscience A/S
· XT-150: Xalud Therapeutics
· Cebranopadol (PRK-101): Tris Pharma
To know more about chronic pain clinical trials, visit @ *Chronic Pain Treatment Drugs** *
*Chronic Pain Market Dynamics*
The chronic pain market dynamics are anticipated to change in the coming years. According to the CDC, in the US itself, around *50 million* adults suffer from chronic daily pain, with approximately *20 million *experiencing high-impact chronic pain that significantly disrupts daily life or work activities. This highlights a *substantial opportunity* in this area. If the drug demonstrates efficacy comparable to opioids but with a superior safety profile, *label expansion* into other indications seems highly likely. There is a latent demand for drugs that are *cost-effective, non-addictive, easy to administer, and free of side effects*. With *over two-thirds of patients* grappling with moderate to severe chronic pain and opioids constituting the primary treatment, both patients and physicians are eagerly anticipating *non-opioid alternatives*.
Furthermore, many potential therapies are being investigated for the treatment of chronic pain, and it is safe to predict that the treatment space will significantly impact the chronic pain market during the forecast period. Moreover, the *anticipated introduction of emerging therapies* with improved efficacy and a further *improvement in the diagnosis rate* are expected to drive the growth of the chronic pain market in the 7MM.
However, several factors may impede the growth of the chronic pain market. The *complexity of diagnosis* is exacerbated by inadequate medical history, the utilization of inappropriate tests, and the presence of multiple diseases, often resulting in *delayed or misdiagnosis*. Additionally, the *unclear correlation between depression and chronic pain complicates symptoms*, *diagnosis, and treatment*, contributing to an elevated *global disease burden.* The significant threat posed to the chronic pain market stems from drug addiction, primarily driven by *opioids and accompanied by substantial health*, societal, and economic consequences.
Moreover, chronic pain treatment poses a *significant economic burden* and disrupts patients’ overall well-being and QOL. Furthermore, the chronic pain market growth may be offset by *failures and discontinuation of emerging therapies*, *unaffordable pricing*, *market access and reimbursement issues*, and a *shortage of healthcare specialists*. In addition, the *undiagnosed, unreported cases and the unawareness* about the disease may also impact the chronic pain market growth.
*Chronic Pain Report Metrics* *Details*
Study Period 2019–2032
Chronic Pain Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Chronic Pain Companies Paradigm Biopharmaceuticals, Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Propella Therapeutics, Amzell, Sorrento Therapeutics, Bayer, Lexicon Pharmaceuticals, Tetra Bio-Pharma, Pure Green Pharmaceuticals, Eli Lilly and Company, Neurofix Pharma, Stayble Therapeutics, Biosplice Therapeutics, Wex Pharmaceuticals, EMD Serono Research & Development Institute, Nordic Bioscience A/S, Xalud Therapeutics, Tris Pharma, and others
Key Chronic Pain Therapies ZILOSUL (pentosan polysulfate sodium), HP-5000 (Diclofenac sodium), Reboxetine (AXS-14), CINGAL, Vixotrigine (BIIB074), TNX-102 SL, TLC599, CNTX-4975, BRIXADI (Buprenorphine, CAM2038), CGS-200-5, AMZ001, Resiniferatoxin (RTX), BAY2395840, LX-9211, QIXLEEF (PPP001), CBD, LY3556050 (CNTX-0290), NFX88, STA363, Lorecivivint (SM04690), Halneuron, Sprifermin, XT-150, Cebranopadol (PRK-101), and others
*Scope of the **Chronic Pain** Market Report*
· *Chronic Pain Therapeutic Assessment: *Chronic Pain current marketed and emerging therapies
· *Chronic Pain* *Market Dynamics:* Attribute Analysis of Emerging Chronic Pain Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Market Access and Reimbursement*
Discover more about chronic pain drugs in development @ *Chronic Pain Clinical Trials*
*Table of Contents*
1. Chronic Pain Market Key Insights
2. Chronic Pain Market Report Introduction
3. Chronic Pain Market Overview at a Glance
4. Chronic Pain Market Executive Summary
5. Disease Background and Overview
6. Chronic Pain Treatment and Management
7. Chronic Pain Epidemiology and Patient Population
8. Patient Journey
9. Chronic Pain Marketed Drugs
10. Chronic Pain Emerging Drugs
11. Seven Major Chronic Pain Market Analysis
12. Chronic Pain Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Related Reports*
*Chronic Pain Epidemiology Forecast*
*Chronic Pain Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted chronic pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
*Chronic Pain Pipeline*
*Chronic Pain Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic pain companies, including *Amzell, Sorrento Therapeutics, Bayer, Lexicon Pharmaceuticals, Tetra Bio-Pharma, Pure Green Pharmaceuticals, Eli Lilly and Company, Neurofix Pharma, Stayble Therapeutics, Biosplice Therapeutics, Wex Pharmaceuticals, EMD Serono Research & Development Institute, *among others.
*Chronic Lower Back Pain Market*
*Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast – 2032 *report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CLBP companies including *Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera,* among others.
*Partial Chronic Pain Market*
*Partial Chronic Pain Market Insights, Epidemiology, and Market Forecast – 2032 *report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key partial Chronic Pain companies, including *GW Pharmaceuticals, Equilibre Biopharmaceuticals,* among others.
*Chronic Lower Back Pain Pipeline*
*Chronic Lower Back Pain Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CLBP companies, including *Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus,* among others.
*Chronic Lower Back Pain Epidemiology*
*Chronic Lower Back Pain Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted CLBP epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
*About DelveInsight*
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*
*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*
CONTACT: Contact Us
Shruti Thakur
info@delveinsight.com
+91-9650213330
www.delveinsight.com